



HAL
open science

Effect of Spironolactone on QRS Duration in Patients at Risk for Heart Failure (from the HOMAGE Trial)

João Pedro Ferreira, John G.F. Cleland, Nicolas Girerd, Pierpaolo Pellicori, Mark R Hazebroek, Job Verdonschot, Timothy J Collier, Johannes Petutschnigg, Andrew L Clark, Jan A Staessen, et al.

► To cite this version:

João Pedro Ferreira, John G.F. Cleland, Nicolas Girerd, Pierpaolo Pellicori, Mark R Hazebroek, et al.. Effect of Spironolactone on QRS Duration in Patients at Risk for Heart Failure (from the HOMAGE Trial). *American Journal of Cardiology*, 2023, 191, pp.39-42. 10.1016/j.amjcard.2022.12.016 . hal-03957590

HAL Id: hal-03957590

<https://hal.univ-lorraine.fr/hal-03957590>

Submitted on 26 Jan 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

Effect of Spironolactone on QRS Duration in Patients at Risk for Heart Failure - findings from the HOMAGE trial

João Pedro Ferreira, MD, PhD^{1,2}; John G. F. Cleland, MD, PhD³; Nicolas Girerd, MD, PhD²; Pierpaolo Pellicori, MD, PhD³; Mark R. Hazebroek, MD, PhD⁴; Job Verdonchot, MD, PhD⁵; Timothy J. Collier, MSc⁶; Johannes Petutschnigg, MD⁷; Andrew L. Clark, MD⁸; Jan A. Staessen, MD, PhD⁹; Stephane Heymans, MD, PhD⁴; Patrick Rossignol, MD, PhD²; Faiez Zannad, MD, PhD²

¹ UnIC@RISE, Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Porto, Portugal.

² INSERM, Centre d'Investigations Cliniques - Plurithématique 14-33, Université de Lorraine, and INSERM U1116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.

³ British Heart Foundation Centre of Research Excellence, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom.

⁴ Department of Cardiology, CARIM, Maastricht University Medical Centre, Maastricht, The Netherlands.

⁵ Department of Clinical Genetics, Maastricht University Medical Centre, Maastricht, The Netherlands.

⁶ London School of Hygiene and Tropical Medicine, London, UK.

⁷ Department of Internal Medicine and Cardiology, Campus Virchow Klinikum, Charité University Medicine Berlin and German Centre for Cardiovascular Research (DZHK), Berlin, Germany.

⁸ Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, UK.

⁹ Non-Profit Research Association Alliance for the Promotion of Preventive Medicine, Mechelen, Belgium.

Correspondence to:

Dr João Pedro Ferreira

CIM - Centro de Investigação Médica

Faculdade de Medicina UP - Piso 6 - DCF

Rua Plácido da Costa, s/n

4200-450 Porto, Portugal

Tel : +351 22 551 3600

Mail: jpferreira@med.up.pt

Abstract

QRS duration can be easily obtained from a 12-lead ECG. Increased QRS duration reflects greater ventricular activation times and often ventricular dyssynchrony. Dyssynchrony causes impairment of global cardiac function and adversely affects prognosis in patients with heart failure (HF). Little is known about the impact of pharmacologic therapies on QRS duration, particularly for patients with pre-symptomatic HF with a preserved LV ejection fraction (i.e., stage B HFpEF). The HOMAGE (Heart OMics in AGEing) trial, enrolled patients with risk factors for developing HF and assigned them to receive either spironolactone or usual care for approximately 9 months in a randomized manner. This analysis reports the effect of spironolactone on QRS duration. A total of 525 patients was included in the analysis. The median (percentile₂₅₋₇₅) QRS duration at baseline was 92 (84-106) ms. Spironolactone reduced QRS duration at month 9 by -2.8, 95%CI -4.6 to -1.0 ms, P =0.003. No significant associations were found between month 9 changes in QRS duration and corresponding changes in left ventricular (LV) ejection fraction, LV mass, LV end-diastolic volume, blood pressure, NT-proBNP, and procollagen type I carboxy-terminal propeptide (all P >0.05). This analysis shows that for patients with stage-B HFpEF, therapy with spironolactone for 9 months shortened QRS duration, an effect that was not associated with reductions in LV mass or volume, supporting the hypothesis that spironolactone has direct beneficial effects to improve myocardial electrical activation in patients with stage B HFpEF.

Key-words: spironolactone; ECG; QRS duration; heart failure.

QRS duration can be easily obtained from a 12-lead ECG. Increased QRS duration reflects greater ventricular activation times. Increases in left ventricular (LV) mass and volume cause subtle increases in QRS duration, which may explain why men have a longer QRS duration than women.¹ Delayed ventricular activation due to bundle-branch block or right ventricular pacing can cause much greater prolongation of the QRS complex, leading to ventricular dyssynchrony. Dyssynchrony causes impairment of global cardiac function and adversely affects prognosis in patients with heart failure (HF) and a dilated left ventricle, which might be improved by cardiac resynchronisation therapy.²⁻⁸ For patients with heart failure and a preserved ejection fraction (HFpEF), there is a linear relation between increasing QRS and worsening prognosis.³ However, little is known about the impact of pharmacologic therapies on QRS duration, particularly for patients with pre-symptomatic HF with a preserved LV ejection fraction (i.e., stage B HFpEF).

HOMAGE (Heart OMics in AGEing; ClinicalTrials.gov Identifier: NCT02556450) was a prospective randomized open-label blinded endpoint (PROBE) trial, enrolling patients with risk factors for developing HF randomly assigned to either spironolactone or usual care (without spironolactone or any other mineralocorticoid receptor antagonist) for approximately 9 months.⁹ Spironolactone reduced markers of collagen synthesis, blood pressure, natriuretic peptide levels, improved cardiac structure and function, and shortened QRS duration.¹⁰

This analysis reports the effect of spironolactone on QRS duration in greater detail. Patient characteristics were compared across tertiles of QRS duration. The effect of spironolactone on changes in QRS duration was studied with analysis of covariance (ANCOVA). Associations between changes in QRS duration and changes in NT-proBNP, echocardiographic measurements, systolic blood pressure

(SBP), and procollagen type I carboxy-terminal propeptide (PICP) were assessed with linear regression models. A P-value <0.05 was considered statistically significant. Analyses were performed using Stata® version 17.1 (StataCorp. 2021).

A total of 525 patients was included in the analysis. The median (percentile₂₅₋₇₅) QRS duration at baseline was 92 (84-106) ms without differences between randomized groups (P =0.33). The baseline QRS duration tertiles were: tertile 1 (n =191): 80 (79-85) ms, tertile 2 (n =163): 92 (90-98) ms, and tertile 3 (n =171): 120 (106-130) ms. Patients with wider QRS were taller (median 166 cm in tertile 1 vs. 171 cm in tertile 3), more often men (60% in tertile 1 vs. 84% in tertile 3), had larger indexed LV end-diastolic volume (median 40 ml/m² in tertile 1 vs. 43 ml/m² in tertile 3), lower ejection fraction (64 % in tertile 1 vs. 61 % in tertile 3), and higher indexed LV mass (median 91 g/m² in tertile 1 vs. 99 g/m² in tertile 3). 22 participants had a pacemaker, most of whom (n =17, 77%) had a wide QRS (tertile 3). No significant differences in age, SBP, NT-proBNP or PICP were observed between groups/tertiles. *Table 1.*

Spironolactone reduced QRS duration at month 9 by -2.8, 95%CI -4.6 to -1.0 ms, P =0.003. By 9 months, QRS increased by 1 ms in control group and decreased by 2 ms in spironolactone group, without significant between-group differences at month 1. *Figure 1.* The reduction in QRS duration was consistent across tertiles (interaction P =0.79), and the effect remained similar after excluding the 22 patients with a pacemaker (β = -2.9, 95%CI -4.6 to -1.2 ms, P =0.001). No significant associations were found between month 9 changes in QRS duration and corresponding changes in LV ejection fraction, LV mass, LV end-diastolic volume, SBP, NT-proBNP, and PICP (all P >0.05).

This analysis shows that for patients with stage-B HFpEF, a longer QRS duration is associated with greater height (and therefore male sex), LV mass, and LV end-diastolic volume and a lower LVEF. Therapy with spironolactone for 9 months shortened QRS duration, an effect that was not associated with reductions in LV mass or volume, supporting the hypothesis that spironolactone has direct beneficial effects to improve myocardial electrical activation in patients with stage B HFpEF.

Ethics approval and consent to participate

The study was approved by all relevant ethics committees and regulatory bodies. All participants provided written informed consent prior to study specific procedures.

Consent for publication

There is no data of individual persons included in the manuscript.

Competing interests

The authors have no relevant conflicts of interest to disclose regarding the content of this manuscript.

References

- (1) Linde, C.; Cleland, J. G. F.; Gold, M. R.; Claude Daubert, J.; Tang, A. S. L.; Young, J. B.; Sherfese, L.; Abraham, W. T. The interaction of sex, height, and QRS duration on the effects of cardiac resynchronization therapy on morbidity and mortality: an individual-patient data meta-analysis. *Eur J Heart Fail* **2018**, *20* (4), 780-791. DOI: 10.1002/ejhf.1133.
- (2) Xiao, H. B.; Roy, C.; Fujimoto, S.; Gibson, D. G. Natural history of abnormal conduction and its relation to prognosis in patients with dilated cardiomyopathy. *Int J Cardiol* **1996**, *53* (2), 163-170. DOI: 10.1016/0167-5273(95)02502-2.
- (3) Joseph, J.; Claggett, B. C.; Anand, I. S.; Fleg, J. L.; Huynh, T.; Desai, A. S.; Solomon, S. D.; O'Meara, E.; McKinlay, S.; Pitt, B.. QRS Duration Is a Predictor of Adverse Outcomes in Heart Failure With Preserved Ejection Fraction. *JACC Heart Fail* **2016**, *4* (6), 477-486. DOI: 10.1016/j.jchf.2016.02.013.
- (4) Cannon, J. A.; Shen, L.; Jhund, P. S.; Anand, I. S.; Komajda, M.; McKelvie, R. S.; Zile, M. R.; Carson, P. E.; McMurray, J. J. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. *Eur J Heart Fail* **2016**, *18* (8), 1021-1031. DOI: 10.1002/ejhf.547.
- (5) Cannon, J. A.; Collier, T. J.; Shen, L.; Swedberg, K.; Krum, H.; Van Veldhuisen, D. J.; Vincent, J.; Pocock, S. J.; Pitt, B.; Zannad, F.. Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). *Eur J Heart Fail* **2015**, *17* (7), 707-716. DOI: 10.1002/ejhf.303.
- (6) Leyva, F.; Boriani, G. The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: insights from an individual patient data meta-analysis of COMPANION and CARE-HF. *Eur J Heart Fail* **2022**, *24* (6), 1091-1093. DOI: 10.1002/ejhf.2536.
- (7) Yancy, C. W.; Jessup, M.; Bozkurt, B.; Butler, J.; Casey, D. E., Jr.; Colvin, M. M.; Drazner, M. H.; Filippatos, G. S.; Fonarow, G. C.; Givertz, M. M.. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. *J Am Coll Cardiol* **2017**, *70* (6), 776-803. DOI: 10.1016/j.jacc.2017.04.025.
- (8) McDonagh, T. A.; Metra, M.; Adamo, M.; Gardner, R. S.; Baumhach, A.; Böhm, M.; Burri, H.; Butler, J.; Čelutkienė, J.; Chioncel, O. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J* **2021**, *42* (36), 3599-3726. DOI: 10.1093/eurheartj/ehab368.
- (9) Pellicori, P.; Ferreira, J. P.; Mariotoni, B.; Brunner-La Rocca, H. P.; Ahmed, F. Z.; Verdonschot, J.; Collier, T.; Cuthbert, J. J.; Petutschnigg, J.; Mujaj, B. Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial. *Eur J Heart Fail* **2020**. DOI: 10.1002/ejhf.1716.
- (10) Cleland, J. G. F.; Ferreira, J. P.; Mariotoni, B.; Pellicori, P.; Cuthbert, J.; Verdonschot, J. A. J.; Petutschnigg, J.; Ahmed, F. Z.; Cosmi, F.; Brunner La Rocca, H. P. The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing

Figure 1




Table 1. Patient's characteristics by QRS tertiles

Characteristic	Tertile 1	Tertile 2	Tertile 3	P-value
N.	191	163	171	
QRS duration, ms	80 (79, 85)	92 (90, 98)	120 (106, 130)	-
Age, years	73 (68, 78)	73 (68, 78)	73 (69, 79)	0.55
Men	115 (60%)	132 (81%)	143 (84%)	<0.001
Height, cm	166 (161, 172)	171 (166, 176)	171 (166, 175)	<0.001
Weight, Kg	78 (67, 87)	83 (74, 92)	83 (75, 96)	<0.001
BMI, Kg/m ²	28 (25, 32)	28 (26, 31)	29 (26, 32)	0.23
Hypertension	152 (80%)	116 (71%)	144 (84%)	0.013
Diabetes mellitus	85 (45%)	63 (39%)	68 (40%)	0.49
Myocardial Infarction	79 (59%)	71 (56%)	63 (54%)	0.76
Stroke	13 (7%)	6 (4%)	9 (5%)	0.43
Pacemaker	1 (1%)	4 (3%)	17 (10%)	<0.001
Beta-blocker	131 (69%)	114 (70%)	119 (70%)	0.96
ACEi/ARB	150 (79%)	120 (74%)	144 (84%)	0.060
Thiazides	35 (18%)	22 (14%)	30 (18%)	0.44
Statin	156 (82%)	144 (88%)	133 (78%)	0.037
SBP, mmHg	140 (127, 156)	140 (128, 156)	140 (129, 154)	0.95
Heart rate, bpm	62 (56, 69)	60 (55, 66)	60 (54, 68)	0.16
LVEF, %	64 (60, 67)	64 (59, 67)	61 (55, 65)	0.002
LVM index, g/m ²	91 (77, 102)	94 (81, 114)	99 (85, 119)	0.001
LVH	43 (24%)	41 (29%)	55 (36%)	0.060
LVEDV index, ml/m ²	40 (34, 46)	42 (36, 52)	43 (36, 49)	0.007
LAVi, ml/m ²	30 (26, 36)	31 (26, 38)	30 (25, 35)	0.23
eGFR, ml/min	73 (62, 84)	77 (63, 86)	72 (59, 85)	0.23
Hemoglobin, g/dl	13.8 (12.9, 14.7)	14.2 (13.3, 15.0)	14.0 (13.1, 15.1)	0.023
Sodium, mmol/L	139 (138, 141)	140 (138, 142)	139 (138, 141)	0.071
Potassium, mmol/L	4.3 (4.1, 4.6)	4.3 (4.1, 4.6)	4.3 (4.1, 4.6)	0.87
NT-proBNP, pg/mL	208 (133, 308)	222 (137, 384)	208 (137, 358)	0.35
PICP, ng/ml	79 (65, 97)	81 (66, 98)	79 (64, 97)	0.74

Legend: ACEi/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker; SBP, systolic blood pressure; LVEF, left ventricular ejection fraction; LVM index, left ventricular mass indexed to body surface area; LVEDV index, left ventricular end-diastolic volume indexed to body surface area; LVH, left ventricular hypertrophy; LAVi, left atrial volume indexed; eGFR, estimated glomerular filtration rate; NT-proBNP, N terminal-pro brain natriuretic peptide; PICP, procollagen type I carboxy-terminal propeptide.